SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miller RW, Young JL Jr., Novakovic B. Childhood cancer. Cancer. 1995; 75(1 Suppl ): 395405.
  • 2
    Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19: 30913102.
  • 3
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694701.
  • 4
    Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003; 21: 7884.
  • 5
    Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22: 28732876.
  • 6
    Spunt SL, Hill DA, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol. 2002; 20: 32253235.
  • 7
    Schabel FM Jr., Griswold DP Jr., Corbett TH, et al. Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Ther. 1983; 20: 283305.
  • 8
    Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with Stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1994; 12: 21262131.
  • 9
    Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 10501058.
  • 10
    O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer. 1977; 39: 19401908.
  • 11
    Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998; 21: 317321.
  • 12
    Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 1995; 15: 697705.
  • 13
    Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999; 17: 27962803.
  • 14
    Womer R, Daller R, Gallagher Fenton J, Miser J. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer. 2000; 36: 8794.
  • 15
    Marina N, Pappo A, Parham D, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol. 1999; 17: 180190.
  • 16
    Krasin MJ, Rodriguez-Galindo C, Davidoff AM, et al. Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatr Blood Cancer. 2004; 43: 229236.
  • 17
    Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003; 55: 168177.
  • 18
    Felgenhauer J, Hawkins D, Pendergrass T, et al. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med Pediatr Oncol. 2000; 34: 2938.
  • 19
    Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer. 2002; 95: 13541365.
  • 20
    Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995; 13: 27962804.
  • 21
    Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol. 1998; 16: 16971706.
  • 22
    Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996; 78: 901911.
  • 23
    Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol. 1992; 10: 17371742.
  • 24
    Gururangan S, Marina NM, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol. 1998; 20: 5561.
  • 25
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 31083114.
  • 26
    Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998; 16: 30443052.
  • 27
    Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer. 2001; 37: 13381344.
  • 28
    Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol. 1990; 8: 443452.
  • 29
    Koscielniak E, Rodary C, Flamant F, et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol. 1992; 20: 209214.
  • 30
    Carli M, Colombatti R, Oberlin O, et al. European Intergroup studies (MMT4–89 and MMT4–91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol. 2004; 22: 47354742.
  • 31
    Schwarz RE, Gerald WL, Kushner BH, et al. Desmoplastic small round cell tumors: prognostic indicators and results of surgical management. Ann Surg Oncol. 1998; 5: 416422.
  • 32
    Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996; 14: 15261531.
  • 33
    Kurre P, Felgenhauer JL, Miser JS, et al. Successful dose-intensive treatment of desmoplastic small round cell tumor in three children. J Pediatr Hematol Oncol. 2000; 22: 446450.
  • 34
    Granowetter L, Womer R, Devidas M, et al. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children's Cancer Group Phase III trial. Med Pediatr Oncol. 2001; 37: 172.
  • 35
    Spunt S, Smith L, Ruymann F, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res. 2004; 10: 60726079.
  • 36
    Hale G, Bowman LC, Stewart C, et al. Cyclophosphamide and targeted dose topotecan with autologous hematopoietic stem cell rescue for solid tumors [abstract]. J Clin Oncol. 2004; 22(14S): 807s.
  • 37
    Weiss RB. Ifosfamide vs cyclophosphamide in cancer therapy. Oncology (Huntington). 1991; 5: 6776.